Dual‐Locking Nanoparticles Disrupt the PD‐1/PD‐L1 Pathway for Efficient Cancer Immunotherapy-Reference-Cited by-同舟云学术

Dual‐Locking Nanoparticles Disrupt the PD‐1/PD‐L1 Pathway for Efficient Cancer Immunotherapy

Published:2019-11-11 Issue:51 Volume:31 Page:1905751
ISSN:0935-9648
Container-title:Advanced Materials
language:en
Short-container-title:Adv. Mater.

Author:

Zhang Zhanzhan¹,Wang Qixue²,Liu Qi¹,Zheng Yadan¹,Zheng Chunxiong¹,Yi Kaikai²,Zhao Yu¹,Gu Yu¹,Wang Ying¹,Wang Chun¹,Zhao Xinzhi¹,Shi Linqi¹,Kang Chunsheng²^ORCID,Liu Yang¹^ORCID

Affiliation:

1. State Key Laboratory of Medicinal Chemical BiologyKey Laboratory of Functional Polymer Materials of Ministry of EducationCollege of ChemistryNankai University Tianjin 300071 China

2. Tianjin Neurological InstituteKey Laboratory of Post‐Neurotrauma Neuro‐Repair and Regeneration in Central Nervous SystemMinistry of Education and Tianjin CityDepartment of NeurosurgeryTianjin Medical University General Hospital Tianjin 300052 China

Funder

National Natural Science Foundation of China

Fundamental Research Funds for the Central Universities

Natural Science Foundation of Tianjin City

Publisher

Wiley

Subject

Mechanical Engineering,Mechanics of Materials,General Materials Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/adma.201905751

Reference39 articles.

1. The CRIPSR /Cas gene‐editing system—an immature but useful toolkit for experimental and clinical medicine